Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878)
Jonathan W. Riess(University of California Davis Medical Center), Primo N. Lara(UC Davis Comprehensive Cancer Center), Harold Keer(Plex Pharmaceuticals (United States)), Karen L. Reckamp(Memorial Sloan Kettering Cancer Center), Jeff Longmate(City of Hope), Caroline Weipert(Guardant (United States)), Edward M. Newman(City of Hope), Paul Frankel(City of Hope), Victoria M. Raymond(Guardant (United States)), Philip C. Mack(UC Davis Comprehensive Cancer Center), Karen A. Kelly(UC Davis Comprehensive Cancer Center), David R. Gandara(University of California, Davis)
Cited by 18
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
|Nature Medicine|2018|1.2k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k